The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
An article from
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
Published July 7, 2026
Getty Images
MeiraGTx is gaining up to $400 million in funding from investment firm Oberland Capital Management to help support the potential launches of gene therapies it’s been developing for inherited eye conditions.
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Aussie super funds hit the jackpot in $2b UK biotech deal
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Correction to Novartis Article
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals
IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport
Novartis acquires British start-up Myricx Bio
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across…
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a…
Novartis has agreed to acquire London biotech Myricx Bio for up to $1.5 billion, believing on its NMT inhibitor payload as a…
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for…
